We performed a cross-sectional study to compare IR and TC between HCV infected (+) children and uninfected (-) controls. Methods: A total of 88 children and young adults (mean age=17.0, SD=5.6) from Boston Children’s Hospital and the University of Miami

were included. Of these, there were 47 HCV infected subjects and 41 uninfected controls matched by age and body mass index (BMI) category. Forty-seven percent of the HCV+ subjects and 34% of the HCV- controls were male. Subjects were excluded if they were undergoing antiviral therapy or if they had other chronic illnesses. HCV viremia was assessed by Cetuximab mouse HCV ribonucleic acid testing. Logistic regression analysis was used to discriminate between HCV+ and HCV- subjects. Independent learn more effects included age, gender, body mass index (BMI), IR estimated using the homeostasis model assessment (loge HOMA2-IR), and TC. Results: After multivariate adjustment for age, BMI, and gender, HCV status was independently

associated with loge HOMA2 IR (χ2(1) = 8.21, p=0.0042). Mean loge HOMA2 IR for HCV+ and HCV- were 0.33 and 0.03, respectively. Total cholesterol was also associated with HCV status (χ2(1) = 4.83, p=0.0279). Mean TC was lower for HCV+ (139mg/dL) than HCV- (154 mg/dL) subjects. Eleven percent of the variance was unique to loge HOMA2-IR and 9% to TC. Total area under the curve was 71% and the full model generalized R2 explained 20% of the HCV between group variance. Positive (65%) and negative (61%) predictive values were approximately equal. Conclusions: HCV infection is independently associated with increased IR and lower total cholesterol among children and young adults even when accounting for potential confounding factors such as age, gender and BMI. Currently, HCV infected children are not routinely evaluated for IR or TC levels. These results support the notion of an HCV associated dysmetabolism that manifests itself even at a young age. Based on our findings, clinicians should strongly consider the possibility of assessing for IR and lipid status among HCV infected children and young adults. Disclosures: Maureen M. Jonas – Advisory Committees medchemexpress or

Review Panels: Gilead Sciences; Consulting: Eisai; Grant/Research Support: Bristol Myers Squibb, Roche, Merck Schering Plough Raymond Chung – Grant/Research Support: Gilead, Mass Biologics, Salix, Ocera The following people have nothing to disclose: Aymin Delgado-Borrego, Roshan Raza, Michelle Godbee, Andrea Barreto, Elsa Yumar, Betania Negre, David A. Ludwig Aims (1) To describe characteristics of adopted children with CHB compared to children living with their birth parents (“not-adopted”). (2) To determine if adoption status is associated with differences in CHB disease phenotype, suggesting the importance of early environmental influences on later disease course. Methods We analyzed baseline data from children enrolled in the HBRN pediatric cohort study at 7 sites in N.